Consensus on patients with hyperuricemia and high cardiovascular risk treatment

Consensus on patients with hyperuricemia and high cardiovascular risk treatment

Substantial amount of epidemiologic studies showed that hyperuricemia is highly associated with cardiovascular disorders, chronic renal disease, and diabetes mellitus development risk. This fact shows necessity of increased focus on uric acid level in serum not only in relation to rheumatic disorder...

Full description

Bibliographic Details
Main Authors:	Irina E Chazova, Juliya V Zhernakova, Oksana A Kisliak, Sergey V Nedogoda, Valery I Podzolkov, Elena V Oshchepkova, Irina V Medvedeva, Olga Iu Mironova, Nataliia V Blinova
Format:	Article
Language:	Russian
Published:	IP Morozov P.V. 2019-12-01
Series:	Системные гипертензии
Subjects:	hyperuricemia uric acid risk factor cardiovascular risk arterial hypertension xanthine oxidase inhibitor allopurinol
Online Access:	https://syst-hypertension.ru/2075-082X/article/viewFile/33536/pdf

Similar Items

To treat or not to treat asymptomatic hyperuricemia
by: Hamid Mustafa
Published: (2014-01-01)

Treatment of asymptomatic hyperuricemia in chronic kidney disease: A new target in an old enemy – A review
by: Maria Erika G. Ramirez, et al.
Published: (2017-09-01)

Hyperuricemia and Progression of Chronic Kidney Disease: A Review from Physiology and Pathogenesis to the Role of Urate-Lowering Therapy
by: Tao Han Lee, et al.
Published: (2021-09-01)

The pattern of allopurinol prescription in a university hospital practice
by: Sahar Ahmed Saad, et al.
Published: (2020-09-01)

Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update
by: Arrigo F. G. Cicero, et al.
Published: (2021-01-01)

Lozartan potential in hyperuricemia correction
by: Sergey Vladimirovich Nedogoda, et al.
Published: (2011-10-01)

Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout
by: Fernando Pérez-Ruiz, et al.
Published: (2019-05-01)

Evaluation of a 12-week allopurinol-lowering therapy in combination with the non-steroidal anti-inflammatory drug meloxicam in patients with gout
by: Margarita A. Gromova, et al.
Published: (2020-07-01)

Comparative Study of Allopurinol and Uralyt-4 in patients with Hyperuricemia in Diyala Governorate.
by: Zuhir M. Hussein, et al.
Published: (2014-04-01)

Actions of Inonotus obliquus against Hyperuricemia through XOD and Bioactives Screened by Molecular Modeling
by: Tianqiao Yong, et al.
Published: (2018-10-01)

Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapy
by: M S Eliseev, et al.
Published: (2019-05-01)

Allopurinol effects on diastolic dysfunction in ESRD patients with hyperuricemia
by: Sattarzade Badkoobeh R, et al.
Published: (2011-01-01)

HYPERURICEMIA AND ITS CORRELATES IN THE RUSSIAN POPULATION (RESULTS OF ESSE-RF EPIDEMIOLOGICAL STUDY)
by: S. A. Shalnova, et al.
Published: (2015-09-01)

Prevalence of Hyperuricemia and the Use of Allopurinol in Older Poles—Results From a Population-Based PolSenior Study
by: Mateusz Winder, et al.
Published: (2021-01-01)

Allopurinol for prevention of progression of kidney disease with hyperuricemia
by: B.H. Santhosh Pai, et al.
Published: (2013-01-01)

Prevalence of hyperuricemia and its correlation with cardiovascular risk factors in Iraqi subjects of karbalaa city.
by: Hedef D. El-Yassin, et al.
Published: (2012-04-01)

Saengmaeksan, a traditional herbal formulation consisting of Panax ginseng, ameliorates hyperuricemia by inhibiting xanthine oxidase activity and enhancing urate excretion in rats
by: Yoon-Young Sung, et al.
Published: (2021-09-01)

HYPERURICEMIA AS A PREDICTOR OF CHRONIC HEART FAILURE
by: M. V. Ledyakhova, et al.
Published: (2015-09-01)

Influence of hyperuricemia treatment on postoperative acute kidney injury among hyperuricemia patients: a single-center retrospective database analysis
by: Shinichiro Watanabe, et al.
Published: (2019-11-01)

Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients
by: Yanchun Li, et al.
Published: (2019-01-01)

Konjac glucomannan improves hyperuricemia through regulating xanthine oxidase, adenosine deaminase and urate transporters in rats
by: Yuan Zhang, et al.
Published: (2018-09-01)

FEBUXOSTAT FOR TREATMENT OF CHRONIC HYPERURICEMIA IN GOUT PATIENTS
by: M. S. Petrova, et al.
Published: (2017-11-01)

Pu-erh ripened tea resists to hyperuricemia through xanthine oxidase and renal urate transporters in hyperuricemic mice
by: Ran Zhao, et al.
Published: (2017-02-01)

Risk factors for primary gout and hyperuricemia
by: Xiang-Lin Yin, et al.
Published: (2020-10-01)

Uric acid, gout and cardiovascular diseases: prospects for the use of urat-lowering medications
by: M. S. Eliseev, et al.
Published: (2019-08-01)

Pharmacological effects of Chatuphalatika in hyperuricemia of gout
by: Vilasinee Hirunpanich Sato, et al.
Published: (2018-01-01)

Xanthine oxidase inhibitors in asymptomatic hyperuricemia
by: O. V. Zhelyabina, et al.
Published: (2019-10-01)

Preventive Effects of Fucoidan and Fucoxanthin on Hyperuricemic Rats Induced by Potassium Oxonate
by: Yung-Tsung Chau, et al.
Published: (2019-06-01)

Old drug, new indication: Olsalazine sodium reduced serum uric acid levels in mice via inhibiting xanthine oxidoreductase activity
by: Yanfen Niu, et al.
Published: (2017-11-01)

Prevalence and Risk Factors Associated with Hyperuricemia in the Pearl River Delta, Guangdong Province, China
by: Liu W, et al.
Published: (2021-02-01)

The prevalence of hyperuricemia and its correlates in Ganzi Tibetan Autonomous Prefecture, Sichuan Province, China
by: Xin Zhang, et al.
Published: (2018-10-01)

Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia and Related Diseases
by: Multidisciplinary Expert Task Force on Hyperuricemia and Related Diseases
Published: (2017-01-01)

Modern paradigm of treatment of hyperuricemia and gout in comorbid patients with the development of cardio-vascular pathology
by: V. I. Mazurov, et al.
Published: (2020-12-01)

Metabolic risks of hyperuricemia
by: L. N. Dolgova, et al.
Published: (2019-12-01)

Hyperuricemia, gout and high cardiovascular risk - how to manage them in clinical practice
by: V V Fomin, et al.
Published: (2019-12-01)

Effects of ChondroT on potassium Oxonate-induced Hyperuricemic mice: downregulation of xanthine oxidase and urate transporter 1
by: Dool-Ri Oh, et al.
Published: (2019-01-01)

Management of hyperuricemia in gout: focus on febuxostat
by: Mattheus K Reinders, et al.
Published: (2010-01-01)

Bioactive Compounds from Plant-Based Functional Foods: A Promising Choice for the Prevention and Management of Hyperuricemia
by: Lin-Lin Jiang, et al.
Published: (2020-07-01)

NEW OPPORTUNITIES FOR CORRECTION OF HYPERURICEMIA IN GOUT
by: Svetlana Evgenyevna Myasoedova, et al.
Published: (2009-12-01)

Phytochemical Screening and Anti-Hyperuricemia Activity Test In Vivo of Ethanolic Extract of Shallot (Allium cepa L.) Skin
by: Syahrina Syahrina, et al.
Published: (2020-08-01)